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Abstract: While porous silica supports have been previously studied as carriers for nanocrystalline
forms of poorly water-soluble active pharmaceutical ingredients (APIs), increasing the loading of
API in these matrices is of great importance if these carriers are to be used in drug formulations.
A dual-stage mixed-suspension, mixed-product removal (MSMPR) crystallizer was designed in which
the poorly soluble API fenofibrate was loaded into the porous matrices of pore sizes 35 nm–300 nm
in the first stage, and then fed to a second stage in which the crystals were further grown in the pores.
This resulted in high loadings of over 50 wt % while still producing nanocrystals confined to the
pores without the formation of bulk-sized crystals on the surface of the porous silica. The principle
was extended to another highly insoluble API, griseofulvin, to improve its loading in porous silica
in a benchtop procedure. This work demonstrates a multi-step crystallization principle API in
porous silica matrices with loadings high enough to produce final dosage forms of these poorly
water-soluble APIs.
Keywords: MSMPR; nanocrystals; confined crystallization
1. Introduction
The low bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs) is a
challenge for API formulation and even selection in the drug discovery phase [1,2]. However, as nearly
90% of drugs in the discovery pipeline have low aqueous solubility [3], finding solutions to improve
the physiochemical properties of these drugs is of high importance [4]. Forming nanocrystals of these
APIs is a simple and promising solution to this problem [5]. Nanocrystalline APIs (<1000 nm) have
improved surface area-to-volume ratios compared to bulk crystals, increasing dissolution rates [6,7],
improving solubility [8–10], and enhancing permeability [11].
Numerous methodologies exist for producing pharmaceutical nanocrystals in both “top-down”
approaches that control the nanosizing of larger crystals or “bottom-up” technologies which
control the size of the crystal formed directly. These methods include milling [5], high-pressure
homogenization [12], hydrosol methods [5,13], freeze-drying [14], supercritical fluid methods [14–16],
and evaporative or antisolvent precipitation [17–21]. These methods have associated problems with
contamination, high surfactant requirements, complex and energy-intensive procedures, difficulties
controlling particle size distribution and polymorphism, and low production rates [22]. Many of
these challenges are addressed with the confined crystallization approach, in which crystallization
of the API is restricted to a micro- or nanoporous environment to form nanocrystals. Of particular
interest and widely studied for drug delivery applications are rigid silica matrices including ordered
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mesoporous silica with and without surface modifications and grain size control [23–29], controlled
pore glass [30–34], and fumed silica [35] due to the high degree of control over pore size and inert
nature leading to nucleation control and polymorph stabilization [36–39].
While many studies have used porous silica matrices with extremely small pores (<10 nm) to confine
high loadings of the amorphous forms of poorly water-soluble drugs to the effect of dramatically
enhanced dissolution profiles [40–44], this study aimed to retain crystallinity of the drug loaded in
porous matrices due to the long-term stability requirements for formulated pharmaceuticals [10,45].
In a previous study, a flow column-based loading process has been developed to first load the poorly
water-soluble API ibuprofen into nanoporous silica and then crystallize the material in the pores
through evaporation [46]. In this process, a maximum loading of about 33 wt % ibuprofen in the silica
matrix was achieved. The researchers found that high API solution concentration and high solvent
viscosity (within common solvents) were able to improve the loading achieved in the pores. Rinse
volume was also a significant process parameter, which needed to be adjusted to be low enough to
maintain drug loading, but high enough to remove bulk micron-sized crystals on the surface of the
silica. This important work is a starting point for the development of continuous flow procedures for
loading API into porous silica matrices.
Based on successful multi-stage continuous crystallizer designs in which the second stage and beyond
aim to grow crystals which have nucleated in a first stage [47–50], a two-stage mixed-suspension,
mixed-product removal (MSMPR) crystallizer was proposed to address the challenge of increasing
the loading of API in porous silica. A single-stage MSMPR was employed for the continuous wetting
of porous silica in a variety of pore sizes with a subsequent filtration step which accomplished
the crystallization of fenofibrate (FEN) within the confined pores by either evaporation or cooling.
This was then coupled to a second stage in which the drug-loaded silica was submerged in a slightly
supersaturated FEN solution, allowing for growth of the nanocrystals within the pores.
Fenofibrate is a biopharmaceutics classification system (BCS) Class II drug (low solubility,
high permeability) used for lowering cholesterol and was chosen for its low aqueous solubility
of 0.8 µg/mL [51]. It has a molecular weight of 360.8 g/mol in a structure with an aromatic portion of
the molecule containing two benzyl rings adjacent to an aliphatic region [52].
The principle was then applied to a bench-scale multiple-step impregnation procedure using an
even less soluble compound, griseofulvin (GSF), to demonstrate improved loadings in this system.
Samples were analyzed with thermogravimetric analysis (TGA) to determine loadings, differential
scanning calorimetry (DSC) to study their nanocrystalline nature, and X-ray powder diffraction (XRPD)
for form identification. This methodology was shown to improve drug loading of poorly water-soluble
compounds, making drug-loaded biocompatible porous silica a viable dosage form.
2. Results
Poorly water-soluble compounds are of interest for confined crystallization work to produce small
crystals with better dissolution ability. In previous studies, FEN nanocrystals confined to rigid porous
silica matrices have been shown to have well-behaved thermal properties and enhanced dissolution
rates [7,40]. A single polymorph has been shown to crystallize in pore sizes from 20 to 300 nm, which
is ideal for studying melting point behavior in a simple system [30].
2.1. Selection of MSMPR Operating Parameters
Experiments were conducted on a Crystal 16 apparatus to determine the saturation solubility and
metastable zone width (MSZW) of the FEN systems. The solubility was measured of FEN in ethyl
acetate alone, and with porous silica also present in the vials. Figure 1 clearly shows the decrease in the
metastable zone width with the addition of porous silica. The need to understand the working MSZW
in a confined crystallization procedure is critical in the selection of a supersaturation level. The feed to
stage two of the crystallizer was carefully selected to lie within the narrowed MSZW resulting from the
presence of silica. This feed was designed to be supersaturated such that the feed could allow growth
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of the FEN crystals in the crystallizer while not dissolving the crystals already loaded in the pores.
It also needed to be stable enough so as to not precipitate on its own. Indeed, some crystallizer runs
were discarded due to issues with bulk crystal formation in the second stage. The saturation solubility
of FEN in ethyl acetate at room temperature (25 ◦C) was found to be approximately 750 mg/mL.
The supersaturation selected for the second-stage feed was about 1.4, a concentration of 1080 mg/mL.
This value was selected to be well within the MSZW window.
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Figure 1. Comparison of the metastable zone width (MSZW) of fenofibrate (FEN) in ethyl acetate
showing a decrease in the width with the addition of porous silica.
The experiments were designed to maintain 10% w/v silica in the crystallizers. It is likely
that the crystallizers could be run at much higher than 10% solids density with similar growth and
loading. The low value of 10% was selected to be conservative in the “infinite solution” approximation
for the second stage, wherein the mecha ics of crystal growth supersaturation were being
careful y monit red.
2.2. Analysis of FEN Loading in MSMPR Experi ents
Table 1 summarizes the loading results from the single- and two-stage MSMPR experiments held
at 25 ◦C as determined by thermogravimetric analysis (TGA). The theoretical maximum loading from
the first stage of the MSMPR was calculated assuming that all of the fenofibrate contained in the
original 600 mg/mL (60% w/v) solution crystallized in the pores and that the pore volume of the silica
was completely filled with solution. The theoretical “filled pore maximum” theoretical loading was
also calculated based on the density of fenofibrate assuming that the entire pore volume was filled
with crystal [53]. This basis is a maximum for comparison; however, complete filling of the tortuous
porous network of the silica would be unlikely.
Only runs which did not show bulk crystallization in the vessels were selected for loading analysis.
However, differential scanning calorimetry (DSC) scans did detect the presence of a small (<10 wt %)
amount of surface crystals present on the silica powder in the 38 and 53 nm samples. This skews
the loading data to suggest slightly higher possible loadings for these two pore sizes. In all pore
sizes, the single-stage MSMPR experiments were able to achieve >75% of the theoretical maximum
loading based on the amount of FEN solution expected to have wetted the pores. The loadings from
the two-stage MSMPR were higher than their one-stage counterpart in all cases, indicating that the
crystals confined to the pores in the first stage were then able to grow within the pores in the second
stage. High weight percentage loadings were achieved in all cases. Most notably, due to its large pore
volume, the porous silica Aeroperl® was able to be loaded with FEN to more than 50 wt % loading.
While the samples with 38 and 53 nm pores did show some surface crystals, the relative contribution
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of surface to confined crystals indicated that there was still growth of the crystals confined to the pores
in the two-stage MSMPR.
Table 1. Room temperature (25 ◦C) mixed-suspension, mixed-product removal (MSMPR) loading
summary of FEN wt % in porous silica.
Pore Size
(nm)
Specific
Surface
Area (m2/g)
Pore Vol.
(mL/g)
Theoretical Single-Stage
Max. Loading from FEN
Soln. (wt %)
Single-Stage
Loading
(wt %)
Theoretical Filled
Pore Max. FEN
Loading (wt %)
Two-Stage
Loading
(wt %)
300 10 1.0 37.5 31.4 ± 1.7 54.1 41.6 ± 1.0
191 30 1.5 47.4 36 ± 1.9 63.9 50.2 ± 1.8
151 31 1.2 41.9 36.1 ± 1.7 58.6 40.2 ± 2.5
105 52 1.4 45.7 36.5 ± 4.2 62.3 54.8 ± 3.7
53 94 1.3 43.8 39.1 ± 1.0 60.5 55.6 ± 2.2
38 138 1.3 43.8 40.3 ± 2.3 60.5 56.1 ± 3.5
35 300 1.6 49.0 - 65.4 56.7 ± 1.6
The single-stage MSMPR was also run at varying filter temperatures for a single pore size of
191 nm. Rather than allowing the crystallization to occur as a result of evaporation of the solvent
and potentially losing more crystals in the wash step, cooling the solution in the crystal pores was
hypothesized to allow for higher loadings even in the single-stage MSMPR. Table 2 summarizes the
loadings determined by TGA and a description of the DSC scans for the varied temperature experiment.
Table 2. Loading results for FEN wt % in porous silica in single-stage MSMPR as a function of
filter temperature.
Temp. (◦C)
Loading (wt %)
Notes from DSC Thermogram
Trial 1 Trial 2 Trial 3 Avg.
25 36.0 42.3 37.2 38.5 ± 3.5 Single peak, confined crystals
20 27.4 30.3 31.8 29.8 ± 2.2 Single peak, confined crystals
18 50.8 48.7 51.6 50.4 ± 1.5 Single peak, confined crystals
17 61.0 58.9 56.9 58.9 ± 2.1 Single peak, confined crystals
15 64.6 61.0 65.7 63.8 ± 2.5 Two peaks, confined and surface crystals
For all temperatures but 15 ◦C, the DSC scans showed single peaks at a melting point depression,
indicating that the crystals formed were confined to the pores of the silica matrix. There is a trend of
higher loadings with cooler filter temperature. The samples crystallized at 15 ◦C were shown to have
two peaks in the DSC scans corresponding to both confined crystals and crystals on the surface of the
porous supports. Previous calculations based on the pore volume and density of FEN indicated that
the theoretical filled pore maximum for FEN entirely occupying the pore volume for this pore size
is 63.9 wt %. The loading values in Trials 1 and 3 at 15 ◦C further support the interpretation of DSC
thermograms, indicating that both confined and surface crystals were present as the measured loading
values exceed the theoretical maximum.
2.3. Dissolution Profile Enhancement
The FEN-loaded silica generated from the MSMPR crystallizers was studied in a dissolution
apparatus to generate the dissolution profiles. Figure 2 shows the dissolution profile of FEN-loaded
Aeroperl® from the two-stage MSMPR in contrast with bulk FEN crystals from the manufacturer.
The Aeroperl® dissolution profiles are the most dramatically enhanced, due to a combination of the
small crystal size (35 nm) and also likely diffusion effects from differences in the tortuosity and porosity
between the different silicas used. The nanocrystalline FEN loaded in Aeroperl® was able to achieve
more than 80% dissolution in 22.5 min, whereas the bulk FEN took 656 min for the same. The release
time for FEN confined to Aeroperl® is the fastest seen of this API confined to any other form of porous
silica [30].
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Figure 2. FEN confined to 35 nm Aeroperl® showing dramatically enhanced dissolution profiles when
compared to the bulk crystals.
2.4. Melting Point Depression Analysis of Nanocrystals with DSC
DSC scans were performed on each sample both to confirm that the crystals formed were confined
to the pores and to study the effect of confinement on melting point depression. For the majority of
the silica supports, the DSC scans showed a single, sharp peak at a melting point below the melting
point of bulk FEN (81.6 ◦C ± 0.2 ◦C). This can be interpreted as indicating the presence of API crystals
confined to the pores, without the presence of significant surface crystals of bulk size on the surface of
the porous silica [30,46]. A few samples from pore sizes 38 and 53 nm showed two peaks on the DSC
scans: a large peak at a temperature bel w 81.6 ◦C and secondary peak at about 81.6 ◦C accounting
for les than 10% of the total peak area. While this is interpreted as the presence of some crystals on
the urface of the porous silica, the small relative quantity was accepted and these samples were still
used for loading analysis.
A basic simplified Gibbs–T omson analy is was employed to study the effect of confinement on
melting point depression of the nanocrystals produced via the MSMPR methods [54]. Equation (1)
relates the melting point depression to the nanocrystal size:
∆Tm = Tm − Tm(d) =
4γsolid−liquid MTm
d∆H f usρsolid
(1)
where Tm is the bulk melting temperature, Tm(d) is the melting temperature of a confined crystal
with diameter d assumed equal to the pore diameter, M is the molecular mass, ρsolid is the density of
the solid, γsolid−liquid is the surface free energy of the solid–liquid interface, and ∆H f us is the molar
enthalpy of fusion.
In previous studies, Equation (1) has been used to fit melting point data to show that the confined
nanocrystals have the expected predictable linear-fit Gibbs–Thomson melting point depressions,
indicating that a decrease in the surface interaction energy of the nanocrystals with the substrate,
found in the numerator, is balanced by a simultaneous decrease in the enthalpy of fusion of the
nanocrystals, found in the denominator. The melting point data from both the single-stage and
two-stage MSMPR were plotte against the inverse of the pore diameter. Figure 3 shows that the
confin d crystals produced by MSMPRs have the expect d melting point depressio behavior with
minimal deviation from the theory and minimal error in melting point temperature within a single
pore size. The fit predicts a bulk melting point of 81.9 ◦C, very close to the measured bulk melting
temperature of 81.6 ◦C.
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(FDA) Class III solvents as challenging systems in which to achieve high pore loadings in a 
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acetone at 25 °C [55,56]. The theoretical maximum loading from the single-pass loading method was 
calculated assuming that all of the GSF or IMC contained in the original undersaturated solution of 
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of confined nanocrystalline FE averaged fro all S PR runs.
2.5. Crystal Form Identification with X-ray Powder Diffraction (XRPD)
All samples showed the same XRPD peak pattern, both within trials of the same size porous
silica and across different pore sizes. Furthermore, the crystal structure was the same regardless of
the number of stages used in the MSMPR setup or the temperature of the filter. Figure 4 shows a
representative scan of each type of experiment conducted (with the baseline silica amorphous feature
present and scaled or shifted for clarity of comparison) showing identical peak patterns. Crystalline
fenofibrate form I has reported theoretical diffractogram main peaks at 12◦ (2θ), 14.5◦ (2θ), 16.2◦ (2θ),
16.8◦ (2θ), and 22.4◦ (2θ) [52]. The identity of all samples of nanocrystalline fenofibrate as form I can
be confirmed by matching peaks and the absence of other peak positions. The high loading of the
single-stage MSMPR run with a cold (17 ◦C) filter for the loading step is evidenced in the relatively
lower amorphous silica underlying baseline contribution to this scan.
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2.6. Extension of Principle to Poorly Soluble Compounds
Griseofulvin (GSF) and indomethacin (IMC) were ch en as compou s that are not only poorly
water-soluble but which also have low solubilities in most of the Food and Drug Administration (FDA)
Class III solvents as challenging systems in which to achieve high pore loadings in a nanoporous
silica matrix. Saturation solubility estimates exist for both APIs of about 40 mg/mL in acetone at
25 ◦C [55,56]. The theoretical maximum loading from the single-pass loading method was calculated
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assuming that all of the GSF or IMC contained in the original undersaturated solution of 30 mg/mL
crystallized in the pore and that the pore volume of the silica was completely filled with solution.
The theoretical “filled pore maximum” theoretical loading was also calculated assuming that the
entirely pore volume was filled with crystals based on the density of GSF, 1.4 mg/mL [57], and
assumed density of 1.0 mg/mL for a conservative estimate for IMC due to lack of available data.
The experiments were all conducted in Aeroperl® of pore size 35 nm to have the highest pore volume
silica (1.6 mL/g). A previous study [58] used IMC as a model compound to test similar loading
procedures; however, this study used silica with smaller pore sizes and did not produce the crystalline
form of drug which was targeted in this work.
Table 3 summarizes the results of the experiments. Extremely low loadings were seen for the
one-pass loading method, attributable to the very low concentration of API in solution. GSF was
loaded to around 3.0 ± 0.6 wt % and the IMC was undetectable in these samples, likely indicating that
what IMC had crystallized from the acetone solution was only on the surface of the porous silica and
was washed off. In the two-pass loading system, the loading of GSF was increased to an appreciable
value greater than 15 wt % and, in the three-pass system, the loading was above 25 wt %. The DSC
thermograms of the loaded samples shown in Figure 5 show that in the two-pass system, all of the
crystalline GSF produced was confined to the pores and showed the characteristic depressed melting
point. However, in the three-pass system, significant surface crystals added to the higher loading
as evidenced by the second peak at the bulk melting temperature. With the two- and three-pass
methods, IMC was detectable in the samples but the DSC thermograms indicated that the majority
of the contribution was from bulk crystals on the surface of the silica or amorphous content and the
methodology was unable to produce IMC nanocrystals confined to the silica pores.
Table 3. Loading results of multi-step procedure for nucleation then growth of crystals to increase the
weight percent loading.
API
Theoret. One-Pass Max.
Load from 30 mg/mL
Soln. (wt %)
Theoret. Filled
Pore Max.
Load (wt %)
One-Pass Loading
(wt %)
Two-Pass
Loading (wt %)
Three-Pass
Loading (wt %)
GSF
4.6 69.1
3.0 ± 0.6 16.9 ± 1.7 26.1 ± 2.0
DSC notes No surface crystals No surface crystals Some surface crystals
IMC
4.6 61.5
- 10.9 ± 2.2 13.2 ± 3.9
DSC notes Undetected Mostly surface crystals Mostly surface crystals
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to bulk crystals show that the two-pass loading technique was able to produce confined nanocrystals
with no significant surface crystals.
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3. Discussion
Fenofibrate was successfully loaded into a range of nanoporous silica with varying pore sizes
using a continuous MSMPR methodology. A single-stage MSMPR was shown to reliably wet the
pores for subsequent crystallization by evaporation to yield average nanocrystalline FEN loadings
across pore sizes of 37 wt % at 25 ◦C. Cooling crystallization was also employed on wetted porous
silica from a single-stage MSMPR to achieve average FEN loadings of 48 wt %. When the single-stage
design was coupled to a second-stage crystallizer in which a supersaturated solution was allowed
to grow the nanocrystals which had already been loaded in the pores, loadings increased without
substantial contributions from crystals on the surface of the porous silica. The average two-stage
MSMPR loading across pore sizes was 51 wt % at 25 ◦C. The nanocrystalline FEN produced was
the same polymorph across all studies and showed the expected melting point depression behavior
expected from a Gibbs–Thomson relationship. A benchtop extension of the principle was shown
to improve the loading of griseofulvin in porous silica from just 3.0 wt % to over 15 wt % with no
surface crystals, but was unable to load the poorly water-soluble drug indomethacin with appreciable
quantities in the pores; indomethacin showed a strong propensity for crystallization on the surface
of the silica related to its nucleation and growth kinetics. Using a multi-stage MSMPR apparatus to
load poorly soluble drugs in silica matrices has the ability to decouple nanocrystal formation from
growth and allow for high drug loadings for these compounds. In particular, a material used in this
study, Aeroperl® 300 Pharma, which not only has the highest pore volume but also meets the United
States Pharmacopeia/National Formulary guidelines, is an attractive matrix for further pursuit for
oral dosage forms.
4. Materials and Methods
4.1. Materials
Fenofibrate (FEN), griseofulvin (GSF) and indomethacin (IMC) were obtained from Xian Shunyi
Bio-chemical Technology Company (Shaanxi, China). Silicon dioxide (silica) particles of varying pore
sizes were obtained from three sources. Controlled pore glass (CPG) was obtained from Millipore
(Billerica, MA, USA) in a pore size of 300 nm. More than 90% of the particle mass by weight fell within
a 120/200 mesh size (75–125 µm). CPG was also obtained from Prime Synthesis (Aston, PA, USA) in
pore sizes of 191.4, 151.5, 105.5, 53.7 and 38.3 nm. All had 100% particle mass with a grain size within
a 120/200 mesh. Both the Millipore and Prime Synthesis materials were produced from borosilicate
glass. At least 80% of the pores were within 10% of the mean pore diameter in pore size. Finally,
Aeroperl® 300 Pharma, a fumed silica, was obtained from Evonik (Essen, Germany) with a pore size of
about 35 nm. These particles had an average grain size of 30 µm. Solvents were purchased at ACS
grade or higher purity from Fisher Scientific (Waltham, MA, USA).
4.2. Experimental Apparatus
4.2.1. Single-Stage MSMPR
A single-stage MSMPR was used to crystallize fenofibrate in porous silica. A 50 mL round-bottomed
water-jacketed reaction vessel with standard dimensions was used with magnetic stir bar and
temperature separately controlled by an external water circulation controller (Thermo Scientific
NESLAB RTE, Waltham, MA, USA). A solids content within the reactor of 10 mg porous silica/mL API
solution was chosen; the empty reactor was primed with 500 mg silica to meet this value. The volume
contribution of the silica content was deemed negligible. Peristaltic pumps (Masterflex P/S, Thermo
Scientific) with Viton tubing (Cole-Parmer, Vernon Hills, IL, USA) were used for solution and slurry
transfer. For the single-stage MSMPR, an undersaturated feed solution of 600 mg/mL fenofibrate in
ethyl acetate was fed to the reactor at a flow rate of 1.7 mL/min to maintain a residence time of 30 min
in the reactor. Slurry was removed intermittently so that every 3 min, 5 mL of slurry (10% of the vessel
Crystals 2017, 7, 131 9 of 14
volume) was removed rapidly near the pump maximum flow rate of about 170 mL/min. After the
liquid level again dropped below the outlet dip tube, the tube was pumped with air to clear remaining
slurry. At this time, a replacement quantity of 50 mg of silica was added to the reactor volume to
maintain the solids density at 10 mg/mL. The temperature of the feed and MSMPR were maintained at
25 ◦C. The pore size of the porous silica was varied to study the effect of confinement and subsequent
crystal size on crystal properties and loading. Figure 6a shows a schematic of the apparatus.
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The slurry removed containing API solution-loaded porous silica was fed to a water-jacketed glass
frit filter connected to an external water circulation temperature control (Thermo Scientific NESLAB
RTE) with qualitative Whatman Grade 1 filter paper (GE Healthcare, Chicago, IL, USA). The filter was
maintained at 25 ◦C. The first ten volumes of recovered slurry were discarded to allow the system
a full residence time turnover. The system was then run for 90 min to capture three full residence
times. This resulted in the capture of 150 mL of slurry containing a total of about 1500 mg porous
silica. The final filter cake was dried in air and washed with 5 mL cold (chilled on ice 0–5 ◦C) ethanol
to wash off residual solvent or surface API crystals from the outside of the porous silica beads. In a
second study, the temperature of the filter was varied below 25 ◦C at a fixed pore volume to induce
crystallization while minimizing solvent evaporation. The powder was then dried in the filter by
flowing air. All experiments were carried out in triplicate.
4.2.2. o-Stage S PR
For the t o-stage S P , t o 50 mL water-jacketed reaction ves els were used. The sa e
peristaltic pu ps, tubing, and external ater te perature circulators ere e ployed. The first stage
as essential y a replica of the single-stage experiment, with a 60 mg/ fi rate i t l cetate
fee ith conti sl s li r silic . r t l filter ere hel at 25 ◦ ith
inter it ent slur y ithdrawals every 3 in of 10 of t e l e f t ct r l e ro s
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silica replaced to the vessel at this time. Due to the inability to continuously harvest the filter cake
of API-loaded porous silica from the first stage for supply to the second stage, the second stage was
time-decoupled from the first to allow for the buildup of enough filtered, loaded material from stage
one to accumulate to be fed to stage two.
The feed to the second stage was a supersaturated solution of fenofibrate in ethyl acetate at
1080 mg/mL and 1.7 mL/min. The second reactor vessel was primed with 500 mg of stage one
API-loaded silica. The same residence time of 30 min was maintained and the reactor was held at
25 ◦C. The same intermittent withdrawal scheme of 5 mL every 3 min was employed. The silica added
to the reactor in 50 mg intervals every 3 min was API-loaded silica from stage one. The slurry was
sent to a water-jacketed glass frit filter with qualitative Grade 1 filter paper (Whatman) maintained
at 25 ◦C with an external water circulation controller (Thermo Scientific NESLAB RTE). The samples
were washed at each withdrawal with 1 mL cold (chilled on ice 0–5 ◦C) ethanol to wash off residual
solution and surface crystals. Figure 6b shows a schematic of the setup. The samples were then dried
in the filter by flowing air. Again, the first ten slurry volumes were discarded. The crystallizer was run
for two complete residence times to utilize all of the recovered loaded silica from stage one, resulting
in approximately 1000 mg of captured material at the end of stage two. Experiments were carried out
in triplicate.
4.2.3. Extension of Principle to Poorly Water-Soluble Compounds
Griseofulvin and indomethacin were selected for a bench scale extension of the multiple-stage
MSMPR principle of a first stage to load the pore with an initial crystalline material and a second stage
to grow the crystals in pores. Single-, double- and triple-pass loading methods were employed for
each system. In the single loading method, a previously established technique [46] was employed of
submerging the particles in a large volume (>250 mL) of undersaturated API solution using a fine
mesh basket. About 1 gram of porous silica particles was immersed in a solution of 30 mg/mL GSF
in acetone using a fine mesh basket uncontrolled at room temperature. The solution was left to wet
and enter the silica pores for 20 min before removing and wicking away excess solution using a paper
towel. After the silica particles were removed from the solution, the particles were rinsed with 2.5 mL
of cold ethanol (chilled on ice 0–5 ◦C). The rinse was wicked away using a paper towel and the porous
silica was removed to dry at room temperature for approximately 15 h.
In the double-pass loading method, prepared loaded samples from a single-pass experiment were
then submerged using the fine mesh basket in a large volume very slightly supersaturated solution of
45 mg/mL GSF in acetone. The samples were held for five days at 25 ◦C in a recirculated water bath
(Thermo Scientific NESLAB RTE) at 25 ◦C. The samples were then removed, solution wicked away,
and rinsed with cold ethanol as above before being separated from any visible bulk crystals and dried
at room temperature for about 15 h. Finally, for the triple-pass loaded systems, a third submersion step
in a slightly more supersaturated GSF solution of 50 mg/mL was completed for another five days, with
subsequent identical wash and dry procedures. The experiments were repeated using IMC solutions
in acetone at the same concentrations for the one-pass, two-pass, and three-pass loading methods.
All experiments were carried out in triplicate.
4.3. Analytical Techniques
4.3.1. X-ray Powder Diffraction
XRPD was performed on all samples using a PANalytical X’Pert PRO (Almelo, The Netherlands)
diffractometer at 45 kV with an anode current of 40 mA. The instrument has a PW3050/60 standard
resolution goniometer and a PW3373/10 Cu LFF DK241245 X-ray tube. Samples were placed on a
spinner stage in reflection mode. Settings on the incident beam path included: soller slit 0.04 rad, mask
fixed 10 mm, programmable divergence slit and fixed 1◦ anti-scatter slit. Settings on the diffracted
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beam path include: soller slit 0.04 rad and programmable anti-scatter slit. The scan was set as a
continuous scan: 2θ angle between 4◦ and 40◦, step size .0167113◦ and a time per step of 31.115 s.
4.3.2. Thermogravimetric Analysis
TGA was performed on a Q500 instrument from TA instruments (Newcastle, DE, USA) connected
with a nitrogen gas cylinder to maintain a flow rate of 25 mL/min to maintain an inert gas environment
in the sample chamber. Between 5 and 10 mg of sample were loaded on platinum sample pans from
TA Instruments. The samples were allowed to equilibrate at 30 ◦C and then heated at 10 ◦C/min to
300 ◦C.
4.3.3. Differential Scanning Calorimetry
A Q2000 instrument from TA instruments was used for the DSC analysis. Inert atmosphere
environment was maintained in the sample chamber using a nitrogen gas cylinder set to a flow rate
of 50 mL/min. An extra refrigerated cooling system (RCS 40, TA Instruments) was used to widen
the available temperature range to between −40 and 400 ◦C. Tzero® pans and lids were used with
~5 mg of sample. A heating rate of 10 ◦C/min was applied and the samples were scanned from −20 to
250 ◦C. When determining the enthalpy of fusion for a given sample, the DSC curve was integrated
for 30 ◦C centered on the melting temperature of each pore size to capture the entire melting event.
An exception to this rule was made in samples with a secondary peak present from surface crystals in
which case the integration limit was set to exclude the secondary melting event.
4.3.4. Solubility Measurements
The saturation solubility for FEN was measured in ethyl acetate at different concentrations by
adding a known amount of FEN and 1 mL of solvent, respectively, to a 1.5 mL glass vial. The vials were
then placed in a Crystal16 (Avantium, Amsterdam, the Netherlands), and the heating and cooling rates
were set to 0.3 ◦C/min. The samples were stirred with a controlled stirring speed of 700 rpm using
magnetic stirring bars. The samples were heated with a heating rate of 0.3 ◦C/min from 5 to 50 ◦C. The
temperature at which the suspension turned into a clear solution was recorded and assumed to be the
saturation temperature. The clear points generated the solubility curve. After a waiting time of 30 min
at 50 ◦C, the clear solution was cooled to 5 ◦C with a cooling rate of 0.3 ◦C/min to recrystallize the
FEN. The cloud point curve was generated as the metastable zone limit (see Section 3 for discussion).
4.3.5. Dissolution Testing
A dissolution test meeting the USP standard for fenofibrate was performed using a USP Dissolution
Apparatus 2 at 37 ◦C. Built-in ultraviolet-visible spectroscopy was used to determine percentage of
dissolved FEN at 286 nm. The dissolution buffer used was 0.025 M sodium dodecyl sulfate solution
(Sigma Aldrich (St. Louis, MO, USA). The dissolution apparatus operated at 75 rpm using 900 mL buffer
solution, which was allowed to equilibrate at temperature before the addition of drug-loaded silica.
Enough sample of FEN-loaded silica was added such that the targeted concentration of fenofibrate in
solution was 15 µg/mL, within the expected linear range. Samples were acquired for about 29 h.
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